Project A.L.S. Announces Research Effort with Lilly Project A.L.S. announced an agreement with Eli Lilly and Company aimed at helping to accelerate the development of potential therapies for the neurodegenerative disease amyotrophic lateral sclerosis (ALS), also known as Lou Gehrigs disease. [Project A.L.S.] Press Release
Life Stem Genetics Announces Collaborative Agreement with American CryoStem Life Stem Genetics, Inc. announced a strategic collaborative agreement with American CryoStem Corporation (CRYO). CRYO is a leading developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries. [Business Wire] Press Release
Actinium Pharmaceuticals Announces Plans for Iomab-B Phase III Pivotal Trial Following Meeting with FDA Actinium Pharmaceuticals, Inc. a biopharmaceutical company developing targeted payload immunotherapeutics for the treatment of advanced cancers, provided a corporate update on its two most advanced clinical programs. Kaushik J. Dave Ph.D., MBA, President and Chief Executive Officer discussed recent progress and outline development plans for the company's clinical stage products: Iomab-B and Actimab-A. [Actinium Pharmaceuticals, Inc.] Press Release
Alnylam Earns $7 Million Milestone Payment from Genzyme for Phase II Success with Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR) Alnylam Pharmaceuticals, Inc. announced that it has earned a $7 million milestone from its partner Genzyme, a Sanofi company, for achieving Phase II success with patisiran (ALN-TTR02). [Alnylam Pharmaceuticals] Press Release
ARMO BioSciences Initiates Phase I Clinical Trial of First-in-Class Cancer Immunotherapy ARMO BioSciences, Inc. announced that it initiated the first cohort of patients with advanced solid tumors in a Phase I clinical trial of AM0010, a PEGylated form of recombinant human interleukin-10. [PR Newswire Association LLC] Press Release
Alliqua Receives License to Celgene Cellular Therapeutics Advanced Wound Care ProductsAlliqua, Inc. entered into a licensing agreement with Celgene Cellular Therapeutics, a subsidiary of Celgene Corporation, whereby Alliqua received the right to develop and market the advanced wound care products Biovance and Extracellular Matrix. [Alliqua Inc.] Press Release
Leading Scientists Join BioResearch Open Access Editorial Board under Editor-in-Chief Robert Lanza Dr. Robert Lanza announced that in addition to the distinguished group of Section Editors, including Alan Russell, James Wilson, and Sir Ian Wilmut, among others, fifteen world renowned experts have joined the new Editorial Board of BioResearch Open Access, including ten members of the National Academy of Sciences and Institute of Medicine. [Mary Ann Liebert, Inc.] Press Release
Allergen Research Corporation Announces $17 Million Series A Financing Allergen Research Corporation announced the successful completion of financing to support its upcoming Phase IIb clinical trial to evaluate peanut allergy oral immunotherapy with characterized peanut allergen, as well as related development projects. [Allergen Research Corporation] Press Release
Regeneus to Fast-Track Human Cells under New Japanese Laws The Japanese parliament has passed new laws that provide a rapid approval process specifically designed for human stem cell therapies. Regenerative medicine company, Regeneus, is ready to move on the opportunity. These new laws give the company a unique opportunity to fast-track the clinical trial and potential approval of its new human off-the-shelf cell therapy to treat osteoarthritis and other inflammatory musculoskeletal conditions into the Japanese market. [Regeneus Ltd.] Press Release
New Japanese Regenerative Medicine Legislation and Commercial Opportunities for Stem Cell Products Regenerative medicine company Mesoblast Limited gave an update on new legislation which provides a framework for accelerated approval of stem cell products in Japan, the world's second-largest mature healthcare market. [Mesoblast Limited] Press Release
Go here to read the rest:
CellTherapyNews — Cell Therapy News Home